RESUMEN
Background: Inflammation is associated with marked changes in cellular thyroid hormone (TH) metabolism in triiodothyronine (T3) target organs. In the hypothalamus, type 2 deiodinase (D2), the main T3 producing enzyme, increases upon inflammation, leading to an increase in local T3 availability, which in turn decreases thyrotropin releasing hormone expression in the paraventricular nucleus. Type 3 deiodinase (D3), the T3 inactivating enzyme, decreases during inflammation, which might also contribute to the increased T3 availability in the hypothalamus. While it is known that D2 is regulated by nuclear factor κB (NF-κB) during inflammation, the underlying mechanisms of D3 regulation are unknown. Therefore, the aim of the present study was to investigate inflammation-induced D3 regulation using in vivo and in vitro models. Methods: Mice were injected with a sublethal dose of bacterial endotoxin (lipopolysaccharide [LPS]) to induce a systemic acute-phase response. A human neuroblastoma (SK-N-AS) cell line was used to test the involvement of the thyroid hormone receptor alpha 1 (TRα1) as well as the activator protein-1 (AP-1) and NF-κB inflammatory pathways in the inflammation-induced decrease of D3. Results: D3 expression in the hypothalamus was decreased 24 hours after LPS injection in mice. This decrease was similar in mice lacking the TRα. Incubation of SK-N-AS cells with LPS robustly decreased both D3 mRNA expression and activity. This led to increased intracellular T3 concentrations. The D3 decrease was prevented when NF-κB or AP-1 was inhibited. TRα1 mRNA expression decreased in SK-N-AS cells incubated with LPS, but knockdown of the TRα in SK-N-AS cells did not prevent the LPS-induced D3 decrease. Conclusions: We conclude that the inflammation-induced D3 decrease in the hypothalamus is mediated by the inflammatory pathways NF-κB and AP-1, but not TRα1. Furthermore, the observed decrease modulates intracellular T3 concentrations. Our results suggest a concerted action of inflammatory modulators to regulate both hypothalamic D2 and D3 activities to increase the local TH concentrations.
Asunto(s)
Hipotálamo/enzimología , Inflamación/metabolismo , Yoduro Peroxidasa/genética , Animales , Línea Celular Tumoral , Regulación hacia Abajo , Femenino , Humanos , Yoduro Peroxidasa/fisiología , Lipopolisacáridos , Masculino , Ratones , FN-kappa B/fisiología , ARN Mensajero/análisis , Transducción de Señal , Receptores alfa de Hormona Tiroidea/fisiología , Factor de Transcripción AP-1/fisiología , Yodotironina Deyodinasa Tipo IIRESUMEN
It is assumed that in mammals the circadian rhythms of peripheral clocks are synchronized to the environment via neural, humoral and/or behavioral outputs of the central pacemaker in the suprachiasmatic nucleus of the hypothalamus (SCN). With regard to the humoral outputs, the daily rhythm of the adrenal hormone corticosterone is considered as an important candidate. To examine whether adrenal hormones are necessary for the maintenance of daily rhythms in gene expression in white adipose tissue (WAT), we used RT-PCR to check rhythmic as well as 24 h mean gene expression in WAT from adrenalectomized (ADX) and sham-operated rats. In addition, we investigated the effect of adrenalectomy on gene expression in the hypothalamic SCN and paraventricular nucleus (PVN). Adrenalectomy hardly affected daily rhythms of clock gene expression in WAT. On the other hand, >80% of the rhythmic metabolic/adipokine genes in WAT lost their daily rhythmicity in ADX rats. Likewise, in the hypothalamus adrenalectomy had no major effects on daily rhythms in gene expression, but it did change the expression level of some of the neuropeptide genes. Together, these data indicate that adrenal hormones are important for the maintenance of daily rhythms in metabolic/adipokine gene expression in WAT, without playing a major role in clock gene expression in either WAT or hypothalamus.
Asunto(s)
Tejido Adiposo Blanco/metabolismo , Adrenalectomía , Relojes Biológicos/genética , Perfilación de la Expresión Génica , Núcleo Hipotalámico Paraventricular/metabolismo , Núcleo Supraquiasmático/metabolismo , Adipoquinas/metabolismo , Animales , Peso Corporal , Encéfalo/metabolismo , Ritmo Circadiano/genética , ADN Complementario/metabolismo , Regulación de la Expresión Génica , Hipotálamo/metabolismo , Masculino , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Reacción en Cadena en Tiempo Real de la Polimerasa , Factores de TiempoRESUMEN
BACKGROUND: The iodine-containing drug amiodarone (Amio) and its noniodine containing analogue dronedarone (Dron) are potent antiarrhythmic drugs. Previous in vivo and in vitro studies have shown that the major metabolite of Amio, desethylamiodarone, acts as a thyroid hormone receptor (TR) α(1) and ß(1) antagonist, whereas the major metabolite of Dron debutyldronedarone acts as a selective TRα(1) antagonist. In the present study, Amio and Dron were used as tools to discriminate between TRα(1) or TRß(1) regulated genes in central and peripheral thyroid hormone metabolism. METHODS: Three groups of male rats received either Amio, Dron, or vehicle by daily intragastric administration for 2 weeks. We assessed the effects of treatment on triiodothyronine (T(3)) and thyroxine (T(4)) plasma and tissue concentrations, deiodinase type 1, 2, and 3 mRNA expressions and activities, and thyroid hormone transporters monocarboxylate transporter 8 (MCT8), monocarboxylate transporter 10 (MCT10), and organic anion transporter 1C1 (OATP1C1). RESULTS: Amio treatment decreased serum T(3), while serum T(4) and thyrotropin (TSH) increased compared to Dron-treated and control rats. At the central level of the hypothalamus-pituitary-thyroid axis, Amio treatment decreased hypothalamic thyrotropin releasing hormone (TRH) expression, while increasing pituitary TSHß and MCT10 mRNA expression. Amio decreased the pituitary D2 activity. By contrast, Dron treatment resulted in decreased hypothalamic TRH mRNA expression only. Upon Amio treatment, liver T(3) concentration decreased substantially compared to Dron and control rats (50%, p<0.01), but liver T(4) concentration was unaffected. In addition, liver D1, mRNA, and activity decreased, while the D3 activity and mRNA increased. Liver MCT8, MCT10, and OATP1C1 mRNA expression were similar between groups. CONCLUSION: Our results suggest an important role for TRα1 in the regulation of hypothalamic TRH mRNA expression, whereas TRß plays a dominant role in pituitary and liver thyroid hormone metabolism.
Asunto(s)
Receptores alfa de Hormona Tiroidea/fisiología , Receptores beta de Hormona Tiroidea/fisiología , Hormonas Tiroideas/metabolismo , Animales , Hipotálamo/metabolismo , Yoduro Peroxidasa/genética , Hígado/metabolismo , Masculino , Hipófisis/metabolismo , ARN Mensajero/análisis , Ratas , Ratas Wistar , Receptores alfa de Hormona Tiroidea/antagonistas & inhibidores , Receptores beta de Hormona Tiroidea/antagonistas & inhibidoresRESUMEN
Excessive secretion of triglyceride-rich very low-density lipoproteins (VLDL-TG) contributes to diabetic dyslipidemia. Earlier studies have indicated a possible role for the hypothalamus and autonomic nervous system in the regulation of VLDL-TG. In the current study, we investigated whether the autonomic nervous system and hypothalamic neuropeptide Y (NPY) release during fasting regulates hepatic VLDL-TG secretion. We report that, in fasted rats, an intact hypothalamic arcuate nucleus and hepatic sympathetic innervation are necessary to maintain VLDL-TG secretion. Furthermore, the hepatic sympathetic innervation is necessary to mediate the stimulatory effect of intracerebroventricular administration of NPY on VLDL-TG secretion. Since the intracerebroventricular administration of NPY increases VLDL-TG secretion by the liver without affecting lipolysis, its effect on lipid metabolism appears to be selective to the liver. Together, our findings indicate that the increased release of NPY during fasting stimulates the sympathetic nervous system to maintain VLDL-TG secretion at a postprandial level.
Asunto(s)
Hipotálamo/metabolismo , Lipoproteínas VLDL/metabolismo , Hígado/metabolismo , Neuropéptido Y/metabolismo , Sistema Nervioso Simpático/fisiología , Triglicéridos/metabolismo , Animales , Glucemia , Privación de Alimentos , Glucosa/metabolismo , Insulina/sangre , Insulina/metabolismo , Hígado/inervación , Masculino , Ratas , Ratas WistarRESUMEN
Decreased serum thyroid hormone concentrations in severely ill patients were first reported in the 1970s, but the functional meaning of the observed changes in thyroid hormone levels, together known as nonthyroidal illness syndrome (NTIS), remains enigmatic. Although the common view was that NTIS results in overall down-regulation of metabolism in order to save energy, recent work has shown a more complex picture. NTIS comprises marked variation in transcriptional and translational activity of genes involved in thyroid hormone metabolism, ranging from inhibition to activation, dependent on the organ or tissue studied. Illness-induced changes in each of these organs appear to be very different during acute or chronic inflammation, adding an additional level of complexity. Organ- and timing-specific changes in the activity of thyroid hormone deiodinating enzymes (deiodinase types 1, 2, and 3) highlight deiodinases as proactive players in the response to illness, whereas the granulocyte is a novel and potentially important cell type involved in NTIS during bacterial infection. Although acute NTIS can be seen as an adaptive response to support the immune response, NTIS may turn disadvantageous when critical illness enters a chronic phase necessitating prolonged life support. For instance, changes in thyroid hormone metabolism in muscle during critical illness may be relevant for the pathogenesis of myopathy associated with prolonged ventilator dependence. This review focuses on NTIS as a timing-related and organ-specific response to illness, occurring independently from the decrease in serum thyroid hormone levels and potentially relevant for disease progression.